Loading...
Market
What strategic actions will Novo Nordisk take post-acquisition of Catalent by end of 2025?
2
Resolution / Starting Odds
Expansion in manufacturing • 25%
New product launches • 25%
Cost-cutting measures • 25%
No major strategic changes • 25%
Press releases from Novo Nordisk or industry reports
Story
Senator Warren Urges FTC to Scrutinize Novo Nordisk's $16.5 Billion Catalent ($CTLT) Deal
Oct 10, 2024, 04:05 PM
US Senator Elizabeth Warren has called for regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's parent foundation would acquire Catalent ($CTLT), a contract drug manufacturer. Warren urged the Federal Trade Commission (FTC) to investigate whether the deal would give Novo Nordisk ($NVO) an unfair advantage in the market for obesity and diabetes drugs. She expressed concerns about the potential control Novo Nordisk would gain over some of Catalent's plants.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Decrease • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Growth above 10% • 25%
Growth 5-10% • 25%
Growth below 5% • 25%
No growth • 25%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
Discontinue development • 25%
Partner with another company • 25%